bioAffinity Technologies will present research at CHEST 2026 showing its sputum-based test in development can measure multiple inflammatory biomarkers, including targets of biologic drugs like Tezspire, Dupixent, and Nucala. The test builds on the CyPath Lung platform. It is investigational and not yet available for clinical use.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
